Compare Li Auto Inc (LI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Summit Therapeutics Inc — how do they compare? Li Auto Inc trades at $11.53 (market cap $10.71B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and Summit Therapeutics Inc for 16 Days on average.
| LI | SMMT | |
|---|---|---|
Market Cap | $10.71B | $13.71B |
Volume | 1,781,143 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.61 | $26.38 |
52-Week Low | $10.69 | $12.43 |
Typical Hold Time | 101 Days | 16 Days |
Enterprise Value | $139.58M | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.54, down 5.0% recently and near 52-week lows amid weak delivery numbers. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal declining revenue from $144.5B in 2024 to $112.3B in 2025 and negative net income margins. Recent news highlights September deliveries of 31,817 vehicles and new model launches like the Li i9 SUV.
Outlook remains challenging with intense EV competition and cash flow concerns, though analyst consensus suggests 32% upside to $15.18 target. Key risks include execution on new models and Chinese market volatility, while the strong balance sheet provides some stability for patient investors.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
